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ABSTRACT
Objective: To identify scientific studies and to deepen the knowledge of peripheral 
neuropathies induced by chemotherapy antineoplastic, seeking evidence for assistance to 
cancer patients. Method: Integrative review of the literature conducted in the databases 
Latin American and Caribbean Health Sciences (LILACS), Scientific Electronic Library 
Online (SciELO), Medical Literature Analysis (PubMed/MEDLINE), the Cochrane 
Library and the Spanish Bibliographic Index Health Sciences (IBECS). Results: The 
sample consisted of 15 studies published between 2005-2014 that met the inclusion 
criteria. Studies showed aspects related to advanced age, main symptoms of neuropathy 
and chemotherapy agents as important adverse effect of neuropathy. Conclusion: We 
identified a small number of studies that addressed the topic, as well as low production 
of evidence related to interventions with positive results. It is considered important to 
develop new studies proposed for the prevention and/or treatment, enabling adjustment 
of the patient’s cancer chemotherapy and consequently better service.
DESCRIPTORS
Peripheral Nervous System Diseases; Drug Therapy; Neoplasms; Oncology Nursing; 
Review.
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INTRODUCTION
Today, cancer is considered a major public health prob-
lem in developed and developing countries, conceptual-
ized as multifactorial pathology and classified as a chronic 
degenerative disease that affects thousands of people an-
nually(1). According to the National Cancer Institute Jose 
Alencar Gomes da Silva (INCA)(2) there are an estimated 
580,000 new cases of cancer in 2014 valid for 2015, data 
from the National Day Against Cancer and the Brazilian 
Ministry of Health. The most prevalent types of cancer in 
the Brazilian population are: skin cancer not melanoma 
(182,000), prostate cancer (69,000), breast cancer (57,000), 
colon and rectum cancers (33,000), lung cancer (27,000) 
and stomach cancer (20,000). Thus, it can be noted that 
the types of cancers in studies are those that occur more 
frequently worldwide(2).
Conventional treatments currently used for cancer 
include surgery, radiotherapy and chemotherapy. New 
therapeutic modalities have been developed, such as tar-
geted therapies that seek to reach only cancer cells. Che-
motherapy is the administration of chemical substances, 
alone or in combination with other drugs that work at 
different stages of the cell cycle in order to treat the dis-
ease systemically(3).
Chemotherapy generally affects not only cancer cells 
but also destroy normal cells, as both these cells (cancer 
and neoplastic cells) follow the same stages of the nor-
mal cell cycle. In the case of neoplastic cells, abnormal 
cell proliferation occurs facilitating tumor growth. Some 
chemotherapeutic agents are intended to work specifi-
cally on cell cycle division phase, preventing the division 
and growth of cell number or by blocking the process, al-
though they may also destroy cells that have been divid-
ed. Thus, these drugs are more effective the earlier they 
are administered. It is known today that rapid growing 
tumors are more sensitive to the action of drugs, which 
results in cell death due to the large number of cells that 
are in the dividing process(4).
Researches show that chemotherapy has been a main-
stay of systemic cancer treatment, but there are studies that 
point to the adverse effects of drugs, which bring various 
adverse effects to patients. Among the most common we 
may mention: nausea and vomiting, fatigue, alopecia, neu-
rogenic pain, diarrhea, constipation, integumentary system 
changes and neurotoxicity(5).
Peripheral neuropathy is one way of presenting neuro-
toxicity; which is the deterioration of the peripheral ner-
vous system (PNS), that is, the degeneration of the nerves 
that carry information from the central nervous system 
(CNS) to the rest of the body, besides conducting the sen-
sitivity of the body. Any degeneration of the PNS affects 
the functions of nerves that are fundamental to the human 
being; peripheral neuropathy distorts and may terminate 
the mutual information between the CNS and the extremi-
ties of the body(6).
There is wide number of neuropathy categories, each 
with its special characteristics such as: established symptoms, 
evolution and prognosis. The symptoms come from the 
affected nerve, being autonomic, motor or sensory(7).
Peripheral neuropathies are caused by chemotherapeutic 
agents which have varying degrees of toxicity, depending 
on the type and binding of used drugs, administration time 
and cumulative dose(8). It may be restricted to the use of 
antineoplastic agents, and often essential reduction of the 
dose being administered, and in some cases, discontinuation 
of treatment due to neuropathy degree(6).
INCA briefly classifies the degrees of peripheral neu-
ropathy in Grade I: decrease in reflexes and light paresthesia; 
Grade II: decrease in sensitivity and intermediate paresthesia; 
Grade III: intense decreased in sensitivity and unbearable par-
esthesia; and Grade IV: absence of reflexes and sensitivity(3).
As described, peripheral neuropathy manifestations are 
associated with the nerve injury which can harm the pa-
tient momentarily or after a long period. Among the most 
common symptoms associated with neuropathy are: muscle 
weakness, painful cramps, twitching, muscle atrophy, bone 
degeneration, changes in skin, hair, nails and sensory and 
autonomic changes(7).
It is observed that peripheral neuropathy is a serious and 
significant neurological adverse effect of chemotherapy(9), so 
it must be monitored from the first symptoms, considering 
that it may worsen during continued treatment(7).
Thus, the objective of this study was to review and syn-
thesize the knowledge of chemotherapy-induced peripheral 
neuropathies (CIPN) used in anticancer treatment, seeking 
evidence for improving care to cancer patients.
METHODS
We used the integrative review method, through studies 
of national and international literature. Integrative review 
involves analysis of research, providing scientific basis for 
decision making, improving the results obtained in clinical 
practice, and prospects for expansion of knowledge in spe-
cific topic, and help to fill gaps identified in previous stud-
ies. The integrative review allows the use of several types of 
studies to evidence a field of study(10).
This method has well defined development stages, such 
as: problem identification/research topic and the rationale 
for the review, search of the scientific literature with prior 
establishment of inclusion and exclusion criteria to point 
and organize primary research on the problem/topic, cat-
egorization/organization/data collection, using a standard 
form to extract information that will be important to ana-
lyze the retrieved studies, assessment/analysis of the collect-
ed data, presentation and comparison of results/interpreta-
tion, presentation of the review/synthesis of knowledge and, 
finally, conclusion(11-12).
Studies were selected according to the following inclu-
sion criteria: primary studies investigating strategies and 
interventions related to the prevention, minimization and 
management/treatment of CIPN and which included the 
following chemotherapy treatment: Paclitaxel, Cisplatin, 
Oxaliplatin and Carboplatin, in the format of scientific re-
search, national and international, published in Portuguese, 
English and Spanish.
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Chart 1 – Characteristics of included studies - Ribeirao Preto, 2014. 
DATABASES TITLE OF STUDY Journal AUTHORS COUNTRY LANGUAGE YEAR INSTITUITION
E1 PUBMED
A randomized, double-blinded, pla-
cebo-controlled phase II trial of re-
combinant human leukemia inhibito-
ry factor (rhuLIF, emfilermin, AM424) 
to prevent chemotherapy-induced 
peripheral neuropathy.
Clinical 
Cancer 
Research
Davis, I. D. 
et al.(14) Australia English 2005
Austin Health 
Studley Road
E2 SCIELO
Is advanced age associated with in-
creased and severity of chemotherapy 
– induced peripheral neuropathy?
Support Care 
Cancer
Argyriou, 
A.A. et 
al.(15)
Greece English 2006
University of 
Patias Medical 
School
E3 PUBMED
Residual neurotoxicity in ovarian can-
cer patients in clinical remission after 
first-line chemotherapy with carbo-
platin and paclitaxel: the Multicenter 
Italian Trial in Ovarian cancer (MITO-
4) retrospective study.
BMC Cancer Pignata, S. et al.(16) Italy English 2006
National 
Cancer 
Institute
E4 MEDLINE
Statistical identification of predictors 
for peripheral neuropathy associated 
with administration of bortezomib, 
taxanes, oxaliplatin or vincristini us-
ing ordered logistic regression analy-
sis.
Anticancer 
Drugs
Kanbayashi, 
Y. et al.(17) Japan English 2010
University 
Hospital Kyoto 
Prefectual
E5 MEDLINE
Clinical randomized controlled study 
on acupuncture for treatment of pe-
ripheral neuropathy induced by che-
motherapeutic drugs.
Znhongguo 
Zhen Jiu.
Xu, W. R. et 
al.(18) China English 2010
Bujing 
University of 
CM
E6 PUBMED
Precise evaluation of chemotherapy-
induced peripheral neuropathy using 
the visual analogue scale: a quantita-
tive and comparative analysis of neu-
ropathy occurring with paclitaxel-car-
boplatin and docetaxel-carboplatin 
therapy.
International 
Journal 
Clinical 
Oncology
Takemoto, 
S. et al.(19) Japan English 2012
University 
School of 
Medicine
E7 MEDLINE Falls in persons with chemotherapy-induced peripheral neuropathy.
Support Care 
Cancer
Tofthagen, 
C; 
Overcash, J; 
Kip, K.(20)
USA English 2012
College of 
Nursing 
University of 
South Florida
E8 MEDLINE
Taxane-induced peripheral neuropa-
thy and health-related quality of life 
in postoperative breast cancer pa-
tients undergoing adjuvant chemo-
therapy: N-SAS BC 02, a randomized 
clinical trial.
Support Care 
Cancer
Shimozuma, 
K. et al.(21) Japan English 2012 _
continued...
Exclusion criteria were: scientific studies regarding pe-
ripheral neuropathy, which were not related to chemother-
apy, published in languages other than those established in 
the inclusion criteria, qualitative studies, literature reviews 
and case reports.
The search was conducted in May/2013 in the electronic 
databases Latin American and Caribbean Health Sciences 
(LILACS), Scientific Electronic Library Online (SciE-
LO), Medical Literature Analysis (PubMed/MEDLINE), 
Cochrane Library, Bibliographical Index Spanish Health 
Sciences (IBECS). For publication purposes, the search 
was extended including latest research results, not delim-
iting the period. In the search, we crossed the following 
descriptors from the Health Science Descriptors (DeCs) 
and MeSH: doença do sistema nervoso periférico (peripheral 
nervous system diseases), quimioterapia (drug therapy), 
neoplasia (neoplasms) and neuropatia periférica (peripheral 
neuropathy) connected by the Boolean operator AND. The 
main question established for this review was: What are the 
available evidence in the literature regarding interventions 
used for the prevention, reduction or treatment/manage-
ment of peripheral neuropathy induced by chemotherapy 
in cancer patients?
Searching the databases, 76 studies were preselected; after 
reading all the titles and then abstracts, 15 primary studies 
were selected according to the inclusion and exclusion criteria.
Studies found in IBECS database were excluded be-
cause they did not fulfil the inclusion criteria; the studies 
found in LILACS and Cochrane databases were not count-
ed because they were duplicated by PubMed/MEDLINE 
and, since the search occurred primarily in the latter data-
bases. Data collection was performed using the proposed 
instrument, developed and validated by Ursi(13).
The final sample consisted of 15 studies related to CIPN 
that focused on the aspects related to prevention, manage-
ment/treatment/intervention and minimization of CIPN, 
described by the authors of the primary studies.
RESULTS
From the collection of information using the above in-
strument, characteristics, analysis and integrative synthesis 
of the studies were conducted. Among the studies found, 
14(93%) were retrieved in PubMed/MEDLINE database.
The characteristics of the included studies used in the 
integrative review are shown in Chart 1.
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...continuation
DATABASES TITLE OF STUDY Journal AUTHORS COUNTRY LANGUAGE YEAR INSTITUITION
E9 PUBMED
Factors exacerbating peripheral neu-
ropathy induced by paclitaxel plus 
carboplatin in non-small cell lung 
cancer.
Oncology 
Research
Kawakami, 
K. et al.(22) Japan English 2012
Cancer 
Institute 
Hospital
E10 MEDLINE
Vitamin E for prevention of oxalipla-
tin-induced peripheral neuropathy: a 
pilot randomized clinical trial.
São Paulo 
Medical 
Journal
Afonseca, S. 
O. et al.(23) Brazil English 2013
Faculdade de 
Medicina do 
ABC
E11 PUBMED
Goshajinkigan oxaliplatin neurotox-
icity evaluation (GONE): a phase 2, 
multicenter, randomized, double-
blind, placebo-controlled trial of 
goshajinkigan to prevent oxaliplatin-
induced neuropathy.
Cancer 
Chemotherapy 
Pharmacology
Kono, T. et 
al.(24) Japan English 2013 -
E12 PUBMED
Phase III randomized, placebo-con-
trolled, double-blind study of intra-
venous calcium and magnesium to 
prevent oxaliplatin-induced sensory 
neurotoxicity (N08CB/Alliance).
Journal 
Geriatric 
Oncology
Loprinzi, C. 
L. et al.(25) USA English 2014
University 
Rochester
E13 PUBMED
Oral alpha-lipoic acid to prevent 
chemotherapy-induced peripheral 
neuropathy: a randomized, double-
blind, placebo-controlled trial.
Support Care 
Cancer
Guo, Y. et 
al.(26) USA English 2014
University of 
Texas
E14 PUBMED
North Central Cancer Treatment 
Group/Alliance trial N08CA-the use 
of glutathione for prevention of pacli-
taxel/carboplatin-induced peripheral 
neuropathy: a phase 3 randomized, 
double-blind, placebo-controlled 
study.
Cancer Leal, A. D. et al.(27) USA English 2014
Mayo Clinic 
Rochester
E15 PUBMED
A phase III randomized, placebo-con-
trolled study of topical amitriptyline 
and ketamine for chemotherapy-in-
duced peripheral neuropathy (CIPN): 
a University of Rochester CCOP study 
of 462 cancer survivors.
Support Care 
Cancer
Gewandter, 
T. S. et 
al.(28)
USA English 2014 University of Rochester
Source: Integrative review study.
Of the 15 studies that comprised the final sample, 14 were 
performed by oncologists, and only one was developed by 
nurses. Publications occurred in several countries, five studies 
in Japan, four in the USA and six distributed in other countries.
As a result of the initial search, studies were found in 
the last two decades, however, after pre-selection, only 15 
studies fulfilled the inclusion criteria for the final sample; 
the publication period was from 2005 to 2014.
Of the 15 studies found, twelve - E2, E4, E5, E6, 
E7, E10, E11, E12, E13, E14 and E15 were performed 
in educational institutions and three - E1, E3 and E9 
in teaching hospitals; E8 does not report the institu-
tion where the research was conducted. Below, Chart 
2 shows information on study design, objectives and 
characteristics of the subjects of the studies included 
in this review:
Chart 2 – Designs and objectives of the studies, characteristics of the study subjects - Ribeirao Preto, 2014. 
 STUDY DESIGN OBJECTIVES CHARACTERISTICS OF SUBJECTS OF RESEARCH AND POLICY PROPOSAL OUTCOMES 
E1 
Randomized 
and exploratory 
clinical study. 
To determine whether the 
recombinant human leu-
kemia inhibitory factor
(rhuLIF) can prevent or 
improve CIPN, treated 
with Paclitaxel and Car-
boplatin. 
117 patients randomly selected according to gender, 
being treated with Carboplatin and Paclitaxel. The 
rhuLIF inhibitor factor was administered subcutane-
ously for seven days, starting one day prior to chemo-
therapy; 36 patients received low doses, 39 patients 
high doses and 42 patients received a placebo. 
The results were not significant 
for the prevention or improve-
ment of CIPN. 
E2 Exploratory clinical study. 
To test the hypothesis that 
advanced age is associ-
ated with the incidence 
and severity of CIPN. 
35 patients of both sexes with lung or breast cancer 
treated with Paclitaxel or Cisplatin, divided between 
under 65 and over or equal to 65 years old. All pa-
tients underwent an evaluation in the third and sixth 
cycle for 3 months after cessation of chemotherapy. 
The researchers found no sig-
nificant data stating the increase 
CIPN in advanced age. 
E3 
Cohort study, 
retrospective 
and exploratory. 
To evaluate/verify the 
residual neuropathy in 
patients with clinical re-
mission in Carboplatin-
Paclitaxel treatment for 
advanced ovarian cancer. 
120 female patients included in the study, all receiv-
ing Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) 
every 3 weeks for 6 cycles, completing treatment be-
tween 1998 and 2003.  
The study revealed that the tox-
icity is caused by the cumulative 
dose in the patient’s body, trig-
gering the process of peripheral 
nerve injury. 
continued...
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 STUDY DESIGN OBJECTIVES CHARACTERISTICS OF SUBJECTS OF RESEARCH AND POLICY PROPOSAL OUTCOMES 
E4 
Retrospective, 
exploratory 
study. 
To statistically identify 
predictors for CIPN. 
Retrospective analysis of 190 patients of both sexes 
treated with Bortezomib, Taxanes, Oxaliplatin or Vin-
cristine, from April 2005 to December 2008.
The study identified as predictors 
for CIPN: paresthesia and dys-
esthesias, numbness, weakness, 
tingling, loss of balance and pain.
E5 
Exploratory and 
comparative 
study. 
To search for effective 
treatment to CIPN using 
acupuncture.  
64 cases of patients with CIPN treated with Pacli-
taxel or Oxaliplatin. Randomly divided into groups, 
32 cases had used acupuncture and other 32 used 
medicines. The neurotoxicity of both groups were 
compared before and after treatment. 
The study achieved significant re-
sults only for acupuncture. 
E6 
Exploratory and 
comparative 
study. 
To investigate whether 
CIPN can be properly as-
sess the usage of the visu-
al analogue scale (VAS).
93 patients of both sexes who were treated with Pacl-
itaxel-Carboplatin (TC) or Paclitaxel-Docetaxel (DC), 
answered a questionnaire about CIPN with VAS, and 
these patients were compared (between those who 
received TC and those who received DC). 
With the use of VAS, it was fa-
cilitated to the researchers to 
conclude that patients with TC 
use had CIPN more aggressive 
compared to those in DC use. 
E7 
Exploratory and 
prospective 
study
To evaluate the possible 
risk factors for falls in a 
group of patients with 
CIPN. 
Study included 109 patients of both sexes who re-
ceived Paclitaxel, Docetaxel, Cisplatin and Oxalipla-
tin or who reported at least one symptom of CIPN. 
Each patient was asked to complete the assessment 
tool of chemotherapy-induced peripheral neuropathy 
(CIPNAT) and a socio-demographic questionnaire. 
Data were analyzed using de-
scriptive statistics and logistic 
regression, analysis could not 
confirm the hypothesis from the 
study. 
E8 Randomized ex-ploratory study. 
To clarify whether adju-
vant monotherapy, based 
on Taxanes, is a viable al-
ternative for the treatment 
of patients in postopera-
tive breast cancer and its 
impact on HRQOL. 
1,060 patients were enrolled, but CIPN and HRQOL 
were evaluated in the first 300 patients; multicenter 
phase III study randomized to one of four adjuvant 
regimens: cyclophosphamide followed by Paclitaxel, 
cyclophosphamide followed by Docetaxel, Paclitaxel 
and Docetaxel. 
The CIPN reported by patients 
were significantly serious in treat-
ment with Taxanes; however, the 
HRQOL results confirmed that 
treatment with a single agent tax-
ane is tolerable. 
E9 Exploratory study. 
To determine when and 
how often CIPN occur in 
patients using Paclitaxel 
+ Carboplatin regimen to 
treat non-small cell lung 
cancer, and the factors 
that aggravate this condi-
tion. 
The sample included 50 patients who received Pacli-
taxel and Carboplatin therapy for treatment of non-
small cell lung cancer. Peripheral neuropathy was 
evaluated by the pharmacist through specific ques-
tionnaire, based on the Common Terminology Criteria 
for Adverse Events version 3.0. 
CIPN was evaluated by the phar-
macist, study of specific questions 
based on the criteria of Common 
Terminology for Adverse Events. 
Univariate analysis was used to 
compare a group without, Grade 
1, Grade 2 or PN (not serious) and 
a group with grade 3 PN (serious). 
E10 
Randomized 
study, explorato-
ry and prospec-
tive pilot type. 
To evaluate the efficacy 
of Vitamin E in the pre-
vention of Oxaliplatin-
induced peripheral neu-
ropathy. 
The study included patients with colorectal and gastric 
cancer who were scheduled to receive chemotherapy 
based on Oxaliplatin. 34 patients were randomized, 
five days before the start of treatment with Oxalipla-
tin, with 16 patients randomized to placebo and 18 
patients to vitamin E until the end of chemotherapy. 
The researchers found no sig-
nificant data stating the increase 
CIPN in advanced age. 
E11 
Randomized, 
double-blind, 
multicenter 
study. 
To estimate improvement 
in CIPN treated with Gos-
hajinkigan (traditional 
Japanese medicine) in 
patients on treatments 
to Oxaliplatin-based ad-
vanced colorectal cancer
The study included 89 patients treated based on Ox-
aliplatin, divided into two groups randomly, 45 pa-
tients receiving oral tablets of placebo and 44 patients 
receiving goshajinkigan to verify the decrease and/or 
improvement in the degree of neuropathy. 
The researchers observed with an 
acceptable safety margin, a sig-
nificant result in the CIPN degree 
of delay without harming the ef-
fectiveness of Oxaliplatin. 
E12 
Randomized, 
double-blind 
study. 
To test the effectiveness 
of calcium and magne-
sium in the prevention of 
CIPN before and after the 
administration of Oxali-
platin. 
353 patients with colon cancer were included in 
use of Oxaliplatin, being randomly divided into two 
groups. In half of the patients were administered in-
travenous calcium and magnesium before and after 
Oxaliplatin, in the other half the same process, but 
with placebo.  
The results were not satisfactory, 
then calcium and magnesium do 
not prevent CIPN.  
E13 
Randomized, 
double-blind 
study. 
To evaluate the admin-
istration of alpha lipoic 
acid (ALA) to decrease 
the symptoms of CIPN 
in patients receiving Cis-
platin regimens and Pa-
clitaxel. 
Included in the study patients with cancer for 18 years 
or more, randomly selected, divided into two groups, 
one receiving 600mg ALA and another group with 
oral placebo, both three times a day for 24 weeks, in 
Cisplatin and Placlitaxel. 
ALA was ineffective to decrease 
the symptoms caused in CIPN in 
patients using Cisplatin and Pa-
clitaxel. 
E14 
Randomized, 
double-blind, 
exploratory 
study. 
To determine whether 
the Glutathione would 
prevent CIPN in patients 
undergoing chemothera-
py with Carboplatin and 
Paclitaxel. 
185 patients received treatment with Carboplatin 
and Paclitaxel, 91 patients received placebo and 94 
glutathione, 15 minutes, immediately before chemo-
therapy, random split. 
No significant differences in both 
groups, glutathione did not pre-
vent patients from developing 
CIPN. 
E15 
Randomized, 
double-blind, 
multicenter 
study. 
To investigate the effect 
of ketamine 2% plus 4% 
amitriptyline cream to re-
duce CIPN. 
There were 462 patients of both sexes who received 
chemotherapy at least for a month, made use of 
ketamine 2%, plus 4% amitriptyline cream, and an-
swered a questionnaire to better assess the symptoms 
(pain, numbness, tingling) for six weeks. 
After six weeks the researchers 
did not obtain any reduction in 
the CIPN symptoms. 
Source: Integrative review study.
...continuation
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Table 1 – Types of cancers in each study of this integrative review - Ribeirao Preto, 2014. 
Type of cancer Id of each study 
Ovarian Cancer E3  
Colorectal/gastric cancer E10, E11, E12 
Lung cancer E2, E9 
Breast cancer E2, E8 
Solid tumors E1 
Not specified E4, E5, E6, E7, E13, E14, E15 
Source: Integrative review studies.
Table 2 – Topics studies - Ribeirao Preto, 2014.
  Topic studied Studies 
1 Advanced age E2, E7 
Symptoms related to CIPN: 
Paresthesia and dysesthesia E3 
Numbness E3, E6, E15 
2 Weakness E3, E7 
Tingling E3, E15 
Loss of balance E7 
Pain E6, E15 
Chemotherapy drug  
Oxaliplatin E4, E5, E7, E10, E11, E12 and E13
3 Paclitaxel E1, E2, E3, E4, E5, E6, E7, E8, E9, E14 
Carboplatin E1, E3, E6, E9, E14 
Cisplatin E2, E7, E13 
4 Cumulative dose E1, E3, E8, E10 
5 Number of cycles E2, E3, E6, E7 
6 Need for Interruption of treatment E8, E10  
7 Intervention E1, E5, E10, E11, E12, E13, E14 and E15. 
Source: Integrative review studies.
Regarding the characteristics of the study participants, 
there was great variation in the number, from 35-300 indi-
viduals within groups of patients. These groups were com-
posed of individuals of both sexes in 12 studies, two devel-
oped only with female participants related to ovarian and 
breast cancers and one study was conducted with only male 
participants. All studies included only participants over 18 
years old. Among the included studies, researches used 
exploratory, randomized, comparative and cohort designs.
The objectives of the 15 studies were clearly stated by 
the authors and presented in Chart 2. In general, the studies 
sought to evaluate the outcomes of interventions, verified 
predictors of CIPN, as well as other factors related to the 
occurrence, incidence and impact on life of patients.
Table 1 shows the types of cancers in which participants 
received chemotherapy in the included studies:
Besides the type of cancer, chemotherapy regimens were 
identified, of which 11 studies included Paclitaxel as treat-
ment regimen chemotherapy. This drug was used alone in 
E8 study, as Oxaliplatin, which was also used alone in E10, 
E11 and E12 studies. The studies E1, E3, E6, E9 and E14 
used the combination of chemotherapy drugs Carboplatin 
and Paclitaxel, corresponding to the most frequently used 
scheme in five studies. The combination of Paclitaxel oc-
curred with Oxaliplatin chemotherapy in E4 and E5 stud-
ies, and Paclitaxel + Oxaliplatin + Cisplatin only in E7. 
Cisplatin + Oxaliplatin in E13 study and finally Paclitaxel 
+ Cisplatin were used in E2.
Considering the peculiarities of topics related to chemo-
therapy used in the studies, the topics that are highlighted 
due to similarity and/or proximity to other research are pre-
sented below:  
Among the factors related to CIPN, the following were 
identified:
1 Advanced age: Three studies which associated advanced 
age to CIPN had different focuses. E2 investigated ad-
vanced age as a factor that favors the development of 
CIPN in patients over 65 years, and E7 associated in-
creased risk of falling in patients who developed CIPN 
in advanced age. Both could not confirm their hypoth-
esis from the study.
2 Symptoms related to CIPN: Four studies analyzed 
associated symptoms were described with CIPN and 
the loss in daily lives of patients in treatment. In these 
analyzes, two or more chemotherapeutic agents for the 
treatment was used, Paclitaxel was present in all studies
3 Chemotherapy agents: The selection of chemotherapy 
agents Paclitaxel, Oxaliplatin, Cisplatin and Carbopla-
tin was established as inclusion criteria, due to the high 
number of studies found that those involved chemo-
therapy in cancer treatment in which patients developed 
CIPN. In the case of this review, 15 studies addressed 
the topic of chemotherapy. As a result of high index of 
chemotherapeutic neurotoxicity used during treatment, 
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symptoms can remain six months to one year depending 
on the amount of chemotherapeutic agent administered.
4 Cumulative dose: The studies E1, E3, E8 and E10 
proposed to investigate the cumulative dose of chemo-
therapy drugs in the body as aggravation of CIPN. These 
studies described that toxicity in the long-term is caused 
by the cumulative dose in the patient’s body, triggering 
the process of peripheral nerve injury described above.
5 Number of cycles: From studies, four chemotherapy 
cycles could thus be seen that the greater the number 
of cycles, the higher the degree of peripheral neuropa-
thy. Only one study associated the number of cycles and 
the chemotherapy used to fall risk; patients who under-
went the treatment based on Paclitaxel, for several cycles 
showed higher risk of falling when compared to patients 
undergoing treatment with other chemotherapy.
6 Need for interruption of treatment: Regarding the 
need for discontinuation of treatment, the E8 and E10 
studies indicate that it is necessary reduction of 25%-
50% of the chemotherapy dose, and depending on the 
severity of symptoms may be a need to stop treatment 
until the patient is better.
7 Intervention: Among the eight studies that performed 
interventions, E1 used the Inhibitory Factor recom-
binant human Leukemia (rhuLIF), aiming to prevent 
or ameliorate CIPN. The E10 used vitamin E to try to 
minimize the CIPN; both results were not significant 
for the prevention of CIPN or even for treatment. The 
E5 compared the efficacy of acupuncture and Cobama-
mina (drug that has antiemetic action and works in the 
CNS and PNS, of neurotrophic and neurogenerative 
way; medication administered intramuscularly, aiming 
to minimize CIPN), and achieved significant results 
only for acupuncture. E11 evaluated treatment with 
Goshajinkigan (traditional Japanese medicine) and had 
a significant improvement in the degree of CIPN of 
patients. The E12 used calcium and magnesium before 
and after the use of Oxaliplatin, and E13 administered 
orally 600mg ALA in patients treated with Cisplatin 
and Oxaliplatin, both not improved their CIPN. E14 
used glutathione 15 minutes before the chemotherapy 
sessions, E15 proposed ketamine 2% + 4% amitriptyline 
cream to reduce CIPN, both studies have not achieved 
positive results.
DISCUSSION
Through the presented results, it is observed that CIPN 
is the focus of only a few studies, mainly developed by 
nurses. However, there was a frequent increase in researches 
when we consider the ones conducted in the last two years 
of this review. The integrative review is a valuable method 
mainly for nursing, because professionals do not usually 
have enough time to search the literature for all scientific 
knowledge on peripheral neuropathies, and even carry out 
a critical analysis of the results of published studies. Thus, it 
is important for health professionals to also dedicate time 
to literature review studies, allowing the disclosure of im-
portant primary research that can help optimize the work 
routine and improve the care provided to patients undergo-
ing chemotherapy(29).
The occurrence of CIPN is one of the major difficulties 
faced by patients undergoing chemotherapy with neurotox-
ic drugs. The high incidence of CIPN associated with the 
use of Paclitaxel, which remains long after the interruption 
of treatment, causes many patients to show losses in their 
daily activities, restricting their social relationships. Recur-
rence of CIPN and aggravation of symptoms, often a result 
in increased morbidity and thus a decrease in quality of life, 
hence the need to decrease therapeutic dose(30).
Maintaining functional autonomy of elderly patients is 
essential, as well as the development of health promotion 
and prevention actions that will help to prevent the risk 
factors and the occurrence of complications of the treat-
ment itself and it can hinder or even disable them to daily 
activities. Often, it is observed that older people are diag-
nosed with cancer late, making preventive interventions or 
minimization of the complications of the disease and the 
adverse effects of chemotherapy difficult(31).
Regarding symptoms related to chemotherapy, we 
highlight six types: paresthesia and dysesthesia, numbness, 
weakness, tingling, loss of balance and pain. The most com-
mon neurotoxicity in patients treated with Carboplatin and 
Paclitaxel is distal sensory neuropathy, that is, a mixture of 
paresthesia and dysesthesia(7). These become more intense 
during the night, so disturbing the sleep of the patient, 
resulting in difficulties in carrying out daily activities and 
consequently impairing the quality of life of these peo-
ple(21). Some studies have reported the numbness with dif-
ferent intensity patterns of neuropathic pain. Anyhow, pain 
sensations and numbness in the feet lead to changes in the 
types of footwear, removal of carpets at home, difficulties 
in running, cycling or standing for prolonged periods(32). 
All these sensations, associated with changes in everyday 
life, also raise the chances of accidents within their own 
homes(5).
The motor toxicity regarded as the most common is 
the weakness associated with distal motor neuropathy. In 
general, patients complain of a slight weakness in only one 
area of the body: the side of the body, limb or muscle, feel-
ing unable to perform their daily activities. Consequently, 
began to consider that are becoming dependent on others(7). 
This new status could impact in deep emotional and social 
changes, leading the patient to retrospection.
Authors from E3 describe the effect of some chemo-
therapy as tingling, which is classified into 4 grades: the 
higher the tingling sensation, the higher the degree, so in 
the grade 4, patients report the sensation to be unbearable 
and therefore interfere with simple activities of everyday. In 
the study mentioned, an intervention to minimize, treat or 
prevent tingling was not proposed, since the objective was 
to evaluate the residual neuropathy in patients treated with 
Paclitaxel and Carboplatin.
The loss of balance is a severe impairment related to 
CIPN, which exposes patients to higher chances to fall with 
fracture possibilities. This restricts their mobility, since be-
fore the insecurity to walk and/or drive, the patient will be 
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restricted to the home or limited to travel long distances, 
requiring the help of others (20).
Pain is a symptom constantly described and reported by 
cancer patients, and may be present in up to 90% of those 
in advanced stages of the disease. Since it is a subjective 
symptom, it is difficult to explain and delineate it, since 
it involves physical, emotional and psychosocial aspects of 
the patient. Pain brings clinical comorbidities, which hinder 
their approach and result in quality of life impairment(33).
Among the chemotherapeutic addressed in the included 
studies, all showed significant occurrence of peripheral neu-
ropathy after administration for a certain period. Virtually 
all patients using Oxaliplatin showed some degree of pe-
ripheral neurological dysfunction, showing the occurrence of 
chronic neuropathy in 29% -70% of patients(24), what draws 
attention due to significant interference in everyday life, in-
cluding social, economic and political aspects that will be af-
fected by this, the need for future studies exploring the topic.
The occurrence of peripheral neurotoxicity up to six 
months after the use of Paclitaxel was 62% in E3 study; 
symptoms related to antineoplastic agent are: tingling, 
numbness and pain in the hands and feet, difficulty walk-
ing, among others. There was a higher incidence of pain 
and numbness in accordance with the studies in patients 
who received Paclitaxel/Carboplatin, and it occurred to 
the extent that the number of cycles increased(5). Thus, it is 
necessary special attention by the whole team treating the 
patient, seeking proper adjustment of dosages, strategies for 
prevention and reduction of symptoms.
The cumulative dose was well demonstrated in E1, E3, 
E8 and E10 studies, which demonstrated the severity of 
the peripheral neuropathies after cumulative doses of drugs. 
Late toxicity struck from 15% to 20% of patients and was 
related to cumulative dose, usually more severe and leading 
to discontinuation of treatment(22).
Depending on the number of cycles, the patient’s toler-
ance and severity of the symptoms presented was indicated 
by dose reduction in 25% to 50% or sometimes interruption 
of risk of progression of cancer(24). This finding highlights 
the need for preventive measures or, early identification of 
the symptoms of CIPN, given its repercussions.
Some patients are afraid to tell what they really feel or 
believe that these symptoms are inherent to the effects of 
anticancer drugs. The relief of adverse events is intended to 
minimize the occurrence, and not adversely affect the results 
of treatment, improving the quality and extending the life 
of these patients.
Given this reality, the oncologist nurse needs to be 
aware of the emergence of cancer treatment complications, 
developing actions that are effective, motivating the pa-
tient to adherence and interventions that can contribute to 
achieving good results. Assess the patient at each cycle of 
treatment, inform symptoms resulting from CIPN, recog-
nize the symptoms and identify actions for early treatment 
will result in the reduction of losses in the activities of daily 
living(34) and will improve the general living conditions.
The field of study, interventions and research is increas-
ingly vast, however, we observed in the literature few studies 
that described the strategies used for prevention, reduction 
or treatment/management of peripheral neuropathy induced 
by chemotherapy. We identified only two studies with posi-
tive results that affect the patient’s response to treatment. 
The need for innovations in research that benefit to obtain 
more reliable data can collaborate with the best quality of life 
of cancer patients(7). Thus, there is the importance of stud-
ies focusing on interventions to minimize the occurrence 
and symptoms of CIPN, during and after chemotherapy.
CONCLUSION
Among the included studies for the integrative review, 
only eight addressed an intervention to minimize and/or 
prevent CIPN. However, six did not produce positive re-
sults, only two studies showed positive interventions and 
contributed to a small but significant improvement in 
CIPN in patients receiving chemotherapy and/or radio-
therapy. Importantly, interventions with positive results 
encourage other researchers on new quests, or even, in the 
improvement of those interventions that are still incipient. 
Although this study has sought evidences for improving the 
quality of care, we emphasize the scarcity of evidence in the 
literature on interventions focusing on prevention, early di-
agnosis and treatment of chemotherapy-induced peripheral 
neuropathy in cancer patients.
We consider essential the development of new research-
es that aim to develop strategies for prevention, reduction of 
occurrences and treatment of CIPN. It is hoped that future 
researches can fill these gaps identifying complications, con-
tributing significantly to improving care of cancer patients.
RESUMO 
Objetivo: Identificar publicações científicas e aprofundar o conhecimento sobre as neuropatias periféricas induzidas por quimioterápicos 
antineoplásicos, buscando subsídios para assistência ao paciente oncológico. Método: Revisão integrativa da literatura realizada nas bases 
de dados Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), Scientific Electronic Library Online (SciELO), 
Medical Literature Analysis (PubMed/MEDLINE), na biblioteca COCHRANE e no  Índice Bibliográfico Espanhol de Ciências 
da Saúde (IBECS).  Resultados: A amostra foi constituída por 15 estudos publicados no período de 2005 a 2014 que atenderam os 
critérios estabelecidos. Os estudos evidenciaram aspectos relacionados à idade avançada dos pacientes, principais sintomas da neuropatia 
e os quimioterápicos que têm a neuropatia como efeito adverso relevante. Conclusão: Identificamos pequeno número de estudos que 
abordavam a temática, assim como baixa produção de evidências relacionadas a intervenções com resultados positivos. Considera-se 
importante o desenvolvimento de novos estudos com propostas de prevenção e/ou tratamento, possibilitando ajustamento do paciente 
à quimioterapia antineoplásica e consequentemente melhor assistência.
DESCRITORES
Doenças do Sistema Nervoso Periférico; Quimioterapia; Neoplasias; Enfermagem Oncológica; Revisão.
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RESUMEN 
Objetivo: Identificar las publicaciones científicas y profundizar el conocimiento acerca de las neuropatías periféricas inducidas por 
quimioterápicos antineoplásicos, buscando subsidios para la asistencia al paciente oncológico. Método: Revisión integradora de la 
literatura realizada en las bases de datos Literatura Latinoamericana y del Caribe en Ciencias de la Salud (LILACS), Scientific Electronic 
Library Online (SciELO), Medical Literature Analysis (PubMed/MEDLINE), en la biblioteca COCHRANE y el Índice Bibliográfico 
Español en Ciencias de la Salud (IBECS).  Resultados: La muestra estuvo constituida de 15 estudios publicados en el período de 2005 
a 2014 que atendieron los criterios establecidos. Los estudios evidenciaron aspectos relacionados con la edad avanzada de los pacientes, 
principales síntomas de la neuropatía y los quimioterápicos que tienen la neuropatía como efecto adverso relevante. Conclusión: 
Identificamos pequeño número de estudios que abordaban la temática, así como poca producción de evidencias relacionadas con las 
intervenciones con resultados positivos. Se considera importante el desarrollo de nuevos estudios con propuestas de prevención y/o 
tratamiento, facilitando la adecuación del paciente a la quimioterapia antineoplásica y consecuentemente una mejor asistencia.
DESCRIPTORES
Enfermedades del Sistema Nervioso Periférico; Quimioterapia; Neoplasias; Enfermería Oncológica; Revisión.
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